working cost-effectiveness study: data sources: studies included as data sources / Meta-analysis: Antiarrhythmic versus control
DISEASE INTERVENTION COMPARISON RESULTS
Cochrane Database Syst Rev. 2007;0(4):CD005049 Systematic Review, Cochrane Review
IN atrial fibrillation, rhythm control strategy The Use of
antiarrhythmic drugs, classes IA, IC, III
As Treatment, Chronic
Is worse Than
placebo or no treatment
To improve mortality: class IA drugs (quinidine, dysopiramide) increased mortality (NNH 109) and the rest did not modify it. All drugs increased adverse effects and pro-arrhythmia (but amiodarone).
Arch Intern Med. 2006 Apr 10;166(7):719-28 Systematic Review
IN atrial fibrillation, rhythm control strategy The Use of
antiarrhythmic drugs, classes IA, IC, III
As Treatment, Chronic
Is worse Than
placebo or no treatment
To reduce mortality, class IA drugs (quinidine, dysopiramide) increased mortality (NNH 109) and the rest did not modify it. All drugs increased adverse effects and pro-arrhythmia (but amiodarone).
J Fam Pract 2000 Nov;49(11):1033-46 Meta-Analysis
IN StudyID: Miller 2000, atrial fibrillation, existing meta-analysis The Use of
diverse antiarrhythmic drugs
As -
Is better Than
placebo or rate control
To maintining sinus rhythm. Not data about mortality or adverse effects.